Table 1 Relationship Between Clinicopathological Features and PD-L1 Expression and Tumor-Infiltrating Lymphocytes in the Entire Cohort
Total (N = 514) | PD-L1 in tumor cells | PD-L1 in immune cells | |||||
positive | negative | positive | negative | ||||
Sex | |||||||
Male | 347 (68%) | 65 (19%) | 282 (81%) | 170 (49%) | 177 (51%) | ||
Female | 167 (32%) | 36 (22%) | 131 (78%) | 74 (44%) | 93 (56%) | ||
Age, median (years, range) | 65 (27–88) | 66 (27–88) | 64 (29–88) | 66 (27–88) | 64 (30–86) | ||
Tumor site | |||||||
Lower 1/3 | 332 (65%) | 63 (19%) | 269 (81%) | 156 (47%) | 176 (53%) | ||
Middle 1/3 | 103 (20%) | 17 (17%) | 86 (83%) | 50 (49%) | 53 (51%) | ||
Upper 1/3 | 79 (15%) | 21 (27%) | 58 (73%) | 38 (48%) | 41 (52%) | ||
Histologic type | * P = 0.008 | * P < 0.001 | |||||
Tubular adenocarcinoma | 415 (81%) | 87 (21%) | 328 (79%) | 214 (52%) | 201 (48%) | ||
Poorly cohesive carcinoma | 83 (16%) | 10 (12%) | 73 (88%) | 22 (27%) | 61 (73%) | ||
Mucinous carcinoma | 9 (2%) | 0 | 9 (100%) | 2 (22%) | 7 (78%) | ||
Undifferentiated carcinoma | 7 (1%) | 4 (57%) | 3 (43%) | 6 (86%) | 1 (14%) | ||
Lauren classification | * P = 0.023 | * P = 0.019 | |||||
Intestinal | 286 (56%) | 46 (16%) | 240 (84%) | 149 (52%) | 137 (48%) | ||
Diffuse | 228 (44%) | 55 (24%) | 173 (76%) | 95 (42%) | 133 (58%) | ||
Lymphatic invasion | * P < 0.001 | ||||||
Present | 230 (45%) | 67 (29%) | 163 (71%) | 100 (43%) | 130 (57%) | ||
Depth of invasion (pT) | * P < 0.001 | * P = 0.006 | |||||
pT1 (mucosa, submucosa) | 262 (51%) | 29 (11%) | 233 (89%) | 137 (52%) | 125 (48%) | ||
pT2 (muscularis proper) | 46 (9%) | 10 (22%) | 36 (78%) | 27 (59%) | 19 (41%) | ||
pT3 (subserosa) | 97 (19%) | 25 (26%) | 72 (74%) | 42 (43%) | 55 (57%) | ||
pT4 (serosa or beyond) | 109 (21%) | 37 (34%) | 72 (66%) | 38 (35%) | 71 (65%) | ||
Lymph node metastasis | * P = 0.008 | * P = 0.004 | |||||
Present | 215 (42%) | 54 (25%) | 161 (75%) | 86 (40%) | 129 (60%) | ||
Tumor stage (pTNM) | * P < 0.001 | * P = 0.008 | |||||
Stage I | 277 (54%) | 36 (13%) | 241 (87%) | 148 (53%) | 129 (47%) | ||
Stage II | 81 (16%) | 23 (28%) | 58 (72%) | 39 (48%) | 42 (52%) | ||
Stage III | 130 (25%) | 33 (25%) | 97 (75%) | 49 (38%) | 81 (62%) | ||
Stage IV | 26 (5%) | 9 (35%) | 17 (65%) | 8 (31%) | 18 (69%) | ||
Total (N = 514) | CD8+ population | FOXP3+ population | PD-1+ population | ||||
high | low | high | low | high | low | ||
Sex | |||||||
Male | 347 (68%) | 177 (51%) | 170 (49%) | 161 (46%) | 186 (54%) | 126 (36%) | 221 (64%) |
Female | 167 (32%) | 80 (48%) | 87 (52%) | 79 (47%) | 88 (53%) | 55 (33%) | 112 (67%) |
Age, median (years, range) | 65 (27–88) | 65 (27–88) | 65 (30–86) | 66 (27–84) | 63 (29–88) | 67 (40–88) | 63 (27–88) |
Tumor site | * P = 0.049 | ||||||
Lower 1/3 | 332 (65%) | 162 (49%) | 170 (51%) | 162 (49%) | 170 (51%) | 108 (33%) | 224 (67%) |
Middle 1/3 | 103 (20%) | 46 (45%) | 57 (55%) | 46 (45%) | 57 (55%) | 37 (36%) | 66 (64%) |
Upper 1/3 | 79 (15%) | 49 (62%) | 30 (38%) | 32 (41%) | 47 (59%) | 36 (46%) | 43 (54%) |
Histologic type | * P = 0.001 | ||||||
Tubular adenocarcinoma | 415 (81%) | 209 (50%) | 206 (50%) | 209 (50%) | 206 (50%) | 152 (37%) | 263 (63%) |
Poorly cohesive carcinoma | 83 (16%) | 37 (45%) | 46 (55%) | 25 (30%) | 58 (70%) | 22 (27%) | 61 (73%) |
Mucinous carcinoma | 9 (2%) | 4 (44%) | 5 (56%) | 3 (33%) | 6 (67%) | 1 (11%) | 8 (89%) |
Undifferentiated carcinoma | 7 (1%) | 7 (100%) | 0 | 3 (43%) | 4 (57%) | 6 (86%) | 1 (14%) |
Lauren classification | * P = 0.004 | * P = 0.002 | |||||
Intestinal | 286 (56%) | 127 (44%) | 159 (56%) | 151 (53%) | 135 (47%) | 97 (34%) | 189 (66%) |
Diffuse | 228 (44%) | 130 (57%) | 98 (43%) | 89 (39%) | 139 (61%) | 84 (37%) | 144 (63%) |
Lymphatic invasion | * P = 0.033 | * P = 0.017 | * P = 0.041 | ||||
Present | 230 (45%) | 127 (55%) | 103 (45%) | 94 (41%) | 136 (59%) | 92 (40%) | 138 (60%) |
Depth of invasion (pT) | * P = 0.006 | * P < 0.001 | |||||
pT1 (mucosa, submucosa) | 262 (51%) | 112 (43%) | 150 (57%) | 152 (58%) | 110 (42%) | 85 (32%) | 177 (68%) |
pT2 (muscularis proper) | 46 (9%) | 31 (67%) | 15 (33%) | 22 (48%) | 24 (52%) | 20 (43%) | 26 (57%) |
pT3 (subserosa) | 97 (19%) | 54 (56%) | 43 (44%) | 34 (35%) | 63 (65%) | 34 (35%) | 63 (65%) |
pT4 (serosa or beyond) | 109 (21%) | 60 (55%) | 49 (45%) | 32 (29%) | 77 (71%) | 42 (39%) | 67 (61%) |
Lymph node metastasis | * P < 0.001 | ||||||
Present | 215 (42%) | 112 (52%) | 103 (48%) | 71 (33%) | 144 (67%) | 77 (36%) | 138 (64%) |
Tumor stage (pTNM) | * P < 0.001 | ||||||
Stage I | 277 (54%) | 126 (45%) | 151 (55%) | 163 (59%) | 114 (41%) | 95 (34%) | 182 (66%) |
Stage II | 81 (16%) | 50 (62%) | 31 (38%) | 29 (36%) | 52 (64%) | 30 (37%) | 51 (63%) |
Stage III | 130 (25%) | 66 (51%) | 64 (49%) | 39 (30%) | 91 (70%) | 44 (34%) | 86 (66%) |
Stage IV | 26 (5%) | 15 (58%) | 11 (42%) | 9 (35%) | 17 (65%) | 12 (46%) | 14 (54%) |